41 completed. 41 Phase 2, 6 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Completed 41 |
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 4 | Completed 4 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 2 | Completed | PATH | 2232 | 2023-03-27 | 2026-09-25 |
| Immunogenicity nOPV2 With and Without bOPV Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV) - Poliomyelitis | Phase 2 | Completed | Centers for Disease Control and Prevention | 795 | 2021-02-08 | 2024-10-04 |
| Clinical Trial of Novel OPV2 Vaccine novel oral polio type 2 vaccine (nOPV2), Placebo - Poliomyelitis | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 330 | 2020-09-21 | 2022-08-30 |
| Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally Inactivated poliovirus vaccine in reduced doses - Polio | Phase 2 | Completed | Instituto Nacional de Saúde, Mozambique | 382 | 2020-08-06 | 2024-01-31 |
| A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine nOPV2 (monovalent oral polio vaccine) - Poliomyelitis | Phase 2 | Completed | Fidec Corporation | 1025 | 2018-12-04 | 2024-01-19 |
| A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Novel OPV2 candidate 1, Novel OPV2 candidate 2, Placebo - Poliomyelitis | Phase 2 | Completed | Pierre Van Damme | 250 | 2018-10-22 | 2021-10-15 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) Uro vaxom, Placebo comparator - UTI, Neurogenic Bladder | Phase 2 | Completed | Buckinghamshire Healthcare NHS Trust | 48 | 2018-04-06 | 2020-03-18 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine. Three-dose regimen of high dosage investigational sIPV, Three-dose regimen of medium dosage investigational sIPV, Three-dose regimen of low dosage investigational sIPV - Polio and Post-Polio Syndrome | Phase 2 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 600 | 2017-12-28 | 2019-04-03 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) sIPV - Polio | Phase 1 / Phase 2 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 60 | 2017-11-24 | 2020-02-11 |
| A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants Inactivated Poliomyelitis Vaccine (Sabin strain), Inactivated Poliomyelitis Vaccine (Salk strain) - Poliomyelitis | Phase 2 / Phase 3 | Completed | LG Chem | 1417 | 2017-05-31 | 2019-08-29 |
| Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Single-dose regimen of high dosage investigational sIPV, Single-dose regimen of medium dosage investigational sIPV, Three-dose regimen of high dosage investigational sIPV - Poliomyelitis | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 708 | 2016-10-01 | 2017-07-26 |
| Safety and Immunogenicity of IPOVAC in Young Children IMOVAC-POLIO, IPOVAC 1.5:5:5, IPOVAC, 3:10:10 - Poliomyelitis | Phase 2 | Completed | National Institute of Hygiene and Epidemiology, Vietnam | 240 | 2015-11-01 | 2017-06-29 |
| 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI, IPV Vaccine SSI - Poliomyelitis | Phase 2 | Completed | Statens Serum Institut | 824 | 2015-02-01 | 2018-11-14 |
| Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life b-OPV, m-OPV2, m-IPV HD - Polio | Phase 2 | Completed | Vaxtrials S.A. | 240 | 2014-04-01 | 2015-07-20 |
| Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Dalfampridine, Placebo - Transverse Myelitis, Neuromyelitis Optica | Phase 2 | Completed | Johns Hopkins University | 24 | 2014-02-01 | 2018-04-17 |
| Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants IPV, Low dose Sabin-IPV, Low dose adjuvanted Sabin-IPV - Poliomyelitis | Phase 1 / Phase 2 | Completed | Pauline Verdijk | 140 | 2012-02-01 | 2014-02-21 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) Live attenuated Poliomyelitis vaccine (Human Diploid Cell), Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell) - Poliomyelitis | Phase 2 / Phase 3 | Completed | Institute of Medical Biology, Chinese Academy of Medical Sciences | 1200 | 2011-01-01 | 2023-10-10 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
Showing 20 of 41. Sign in to see all of them.
Poliomyelitis (32) · Diphtheria (15) · Tetanus (15) · Hepatitis B (14) · Haemophilus Infections (12) · Whooping Cough (7) · Paraparesis, Tropical Spastic (3) · Encephalitis (2) · Myelitis, Transverse (2) · Postpoliomyelitis Syndrome (2) · Virus Diseases (2) · Fever (1) · HTLV-I Infections (1) · Meningitis, Meningococcal (1)
Central Nervous System Diseases (41) · Central Nervous System Infections (41) · Infections (41) · Nervous System Diseases (41) · Neuroinflammatory Diseases (41) · Spinal Cord Diseases (40) · RNA Virus Infections (37) · Virus Diseases (36) · Enterovirus Infections (34) · Neuromuscular Diseases (34) · Picornaviridae Infections (34) · Actinomycetales Infections (15) · Bacterial Infections (15) · Bacterial Infections and Mycoses (15)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (8) · Poliovirus Vaccine, Inactivated (7) · 13-valent pneumococcal vaccine (3) · 10-valent pneumococcal vaccine (1) · 4-Aminopyridine (1) · Cyclosporine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Hepatitis B Vaccines (1) · Immunoglobulins, Intravenous (1) · Meningococcal Vaccines (1) · OM 89 (1) · PHiD-CV vaccine (1)
GlaxoSmithKline (9) · Sanofi Pasteur, a Sanofi Company (5) · Imperial College London (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · LG Chem (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Buckinghamshire Healthcare NHS Trust (1) · Centers for Disease Control and Prevention (1) · Chinese Academy of Medical Sciences (1) · Fidec Corporation (1) · Haukeland University Hospital (1) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · Instituto Nacional de Saúde, Mozambique (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Johns Hopkins University (1)
United States (6) · China (5) · Canada (4) · Finland (4) · Bangladesh (3) · Dominican Republic (3) · Philippines (3) · Poland (3) · United Kingdom (3) · Germany (2) · Panama (2) · Argentina (1) · Belgium (1) · France (1) · Mozambique (1)
Amanda Wilkinson, PhD (1) · Dang D Anh, PhD (1) · Edison Alberto, MD (1) · Edna Viegas, MD,PhD (1) · Elisabeth Farbu, MD, PhD (1) · Fengcai Zhu, Master (1) · Graham P Taylor (1) · Graham P Taylor, FRCP (1) · Ingrid Kromann (1) · Jingsi Yang (1) · Josefina Carlos, MD (1) · K Zaman, PhD FRCP (1) · K. Zaman, MBBS, MPH, PhD, FRCP (1)
PMID 22153001, PMID 28340322, PMID 32867698, PMID 40318674, PMID 16984654, PMID 21372751, PMID 22158682, PMID 22720101, PMID 23241989, PMID 24346596, PMID 24884681, PMID 25043278, PMID 25540274, PMID 26719058, PMID 28419204, PMID 28454674, PMID 29304199, PMID 30249424, PMID 33308427, PMID 33308429, PMID 33351072, PMID 36332645, PMID 36495882, PMID 37178706, PMID 38218668
2009 (1), 2014 (1), 2018 (1)